Optiscan Imaging to market InVivage imaging device

Confocal microscopy manufacturer Optiscan Imaging has moved to list its new oral tissue imaging device for sale in the United States.

The Mulgrave, Melbourne company announced its submission of its US Food and Drug Administration pre-market notification (510(k)) application for its ultra small InVivage imaging device (pictured).

Billed as the next generation, non invasive instantaneous form of oral imaging, InVivage targets the severe health consequences of late-stage diagnosis or oral cancers and pre-cancerous lesions.

The hand held device – about the size of a pen – enables surgeons and physicians to image in real time at a sub-cellular level tissues in the mouth.

This aids rapid diagnosis and surgery to identify cancerous and pre-cancerous tissues, and their margins in the mouth – that is delineating the extent of cancerous or pre-cancerous cells.

The system can be used while a surgeon is operating on a patient.

Optiscan managing director Professor Camile Farah said: “I am delighted to announce the submission of our…application for InVivage, a truly landmark achievement for the company.

“This is a key step towards strengthening the commercialisation of the InVivage device and bringing our revolutionary imaging and real-time pathology technology to the world.

‘This submission strengthens the path for commercialisation of InVivage, which is aligned with our new strategic direction, as we continue to move forward in out go to market plans as well as actively look to diversify our product offering.”

Oprtiscan plans to pursue approvals for other markets ‘at a later point in time’.

Picture: Optiscan Imaging/InVivage

Subscribe to our free @AuManufacturing newsletter here.